Angelita Poston-Seitz
Infectious Disease · Tucson, AZNPI 1063984029
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 39 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 16 manufacturers, the largest accounting for just 18.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $354 and has fallen 65.5% since, to $122 in 2024.
Across 39 payments — averaging $19.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$139
- Viiv Healthcare Company$122
- AstraZeneca$91
- Novo Nordisk$68
- Lilly USA, LLC$50
- AbbVie$48
- plus $252 from 10 others
What the payments were for
- Food & beverage$770100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 9 | $139 |
| Viiv Healthcare Company | 1 | $122 |
| AstraZeneca(2 entities) | 6 | $91 |
| Novo Nordisk | 5 | $68 |
| Lilly USA, LLC | 3 | $50 |
| AbbVie | 2 | $48 |
| Janssen Scientific Affairs, LLC | 1 | $44 |
| Boehringer Ingelheim | 2 | $33 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $31 |
| Amarin Pharma, Inc. | 2 | $28 |
| Eisai Inc. | 2 | $27 |
| Johnson & Johnson | 1 | $20 |
| Sanofi-aventis U.S. LLC | 1 | $20 |
| Amgen | 1 | $17 |
| Mylan Specialty L.p. | 1 | $17 |
| Pfizer | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- APRETUDE$122
How this compares
$770 in reported general payments places this provider in the 65th percentile of 146 infectious disease providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 248 | $996,608 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 171 | $625,494 |
| DescovyEmtricitabine/Tenofov Alafenam | 128 | $290,428 |
| DovatoDolutegravir Sodium/Lamivudine | 75 | $231,889 |
| TivicayDolutegravir Sodium | 84 | $210,894 |
| JulucaDolutegravir/Rilpivirine | 49 | $178,994 |
| IsentressRaltegravir Potassium | 61 | $129,622 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 34 | $120,033 |
| MounjaroTirzepatide | 65 | $109,834 |
| CabenuvaCabotegravir/Rilpivirine | 18 | $108,926 |
| PrezcobixDarunavir/Cobicistat | 22 | $56,370 |
| JardianceEmpagliflozin | 43 | $55,097 |
| OzempicSemaglutide | 29 | $53,805 |
| MytesiCrofelemer | 16 | $45,426 |
| Isentress HdRaltegravir Potassium | 20 | $38,194 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Viiv Healthcare CompanyTriumeq, Dovato, Tivicay, Juluca, Cabenuva | $122 | $1,356,197397 claims |
| Lilly USA, LLCMounjaro, Trulicity | $50 | $144,88787 claims |
| Johnson & JohnsonPrezcobix, Xarelto | $20 | $80,53139 claims |
| Boehringer IngelheimJardiance | $33 | $55,09743 claims |
| Novo NordiskOzempic | $68 | $53,80529 claims |
| PfizerEliquis | $15 | $22,90218 claims |
| GSKTrelegy Ellipta | $139 | $22,54427 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 146 infectious disease providers in Arizona.
Other infectious disease in Tucson
- Mohanad Al-ObaidiTucson$3K
- Logan FelixTucson$2K
- Sudha NagalingamTucson$2K
- Marcelo NasifTucson$1K
- Richard MandelTucson$1K
- Steven OscherwitzTucson$1K
- Laura ValdiviaTucson$1K
- Vimbai NyembaTucson$806
- Janin StrumingerTucson$805
- Clifford MartinTucson$775
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.